KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Edwards Lifesciences (EW) Net Margin (2016 - 2025)

Edwards Lifesciences has reported Net Margin over the past 17 years, most recently at 1.72% for Q4 2025.

  • For Q4 2025, Net Margin fell 112.0% year-over-year to 1.72%; the TTM value through Dec 2025 reached 0.22%, down 5077.0%, while the annual FY2025 figure was 0.22%, 5077.0% down from the prior year.
  • Net Margin for Q4 2025 was 1.72% at Edwards Lifesciences, up from 0.13% in the prior quarter.
  • Over five years, Net Margin peaked at 199.89% in Q3 2024 and troughed at 0.51% in Q1 2025.
  • A 5-year average of 26.76% and a median of 14.72% in 2023 define the central range for Net Margin.
  • Biggest five-year swings in Net Margin: surged 19596bps in 2024 and later plummeted -20002bps in 2025.
  • Year by year, Net Margin stood at 25.22% in 2021, then skyrocketed by 268bps to 92.67% in 2022, then crashed by -97bps to 2.89% in 2023, then decreased by -2bps to 2.84% in 2024, then tumbled by -39bps to 1.72% in 2025.
  • Business Quant data shows Net Margin for EW at 1.72% in Q4 2025, 0.13% in Q3 2025, and 0.29% in Q2 2025.